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Metabolism and Toxicity of
2,2,2-Trifluoroethyl Vinyl Ether
by Vera Fiserova-Bergerova*
A review on metabolism and toxicity of the fluorinated anesthetic agent, fluroxene, is presented.
Fluroxene anesthesia is nontoxic to man but fatal to many experimental animals. The fluroxene molecule
(2,2,2-trifluoroethyl vinyl ether) is composed of two moieties; both are toxic as a result of their
metabolism: the vinyl moiety destroys heme of cytochrome P-450 while being metabolized to the final
product, CO2. The trifluoroethyl moiety is oxidized to trifluoroethanol (TFE) and trifluoroacetic acid
(TFAA), and the acute toxicity offluroxene is related to this pathway. The ratio of metabolites (TFAA to
TFE) excreted by different species exposed to fluroxene varies; whenever highly toxic TFE is the major
metabolite, fluroxene toxicity is high (rodents, dogs, phenobarbital pretreated monkeys), whenever
TFAA is the major metabolite (man, monkey) fluroxene is not toxic. Toxicity in different species also
correlates with the extent of glutathione depletion following fluroxene exposure.
Fluroxene metabolism and toxicity are modified by drugs metabolized by or affecting the activity ofthe
microsomal cytochrome P-450-system or enzymes involved in ethanol metabolism. The susceptibility of
fluroxene to two enzymatic systems which are modified by environmental and genetic factors may explain
the large differences in fluroxene toxicity to various species.
The fate of one-third of fluroxene administered to man remains unknown.
Trifluoroethyl vinyl ether, fluroxene, was intro-
duced in 1953 as the first fluorinated inhalation
anesthetic (1), under the trade name Fluoromar. It
is slightly flammable, but was considered to be an
anesthetic agent of high clinical safety. In 1975,
after enflurane had appeared on the market, the
manufacture of fluroxene was discontinued. The
22-year history offluroxene (Table 1) is an interest-
ing one. During this period, fluroxene was found to
be toxic to surgical patients in only four cases, and
in these four cases other medications were involved
(9, 10, 13, 14). As good as this record is, fluroxene
would never have been approved for use in humans
if it had to undergo present-day testing standards,
because it happens to be highly toxic to experimen-
tal animals (recognized in 1972) (7) and is exten-
sively metabolized to highly toxic metabolites (dis-
covered in 1967) (5).
Metabolites of Fluroxene
When labeled fluroxene was injected into mice
and dogs, trifluoroacetic acid (TFAA) and tri-
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fluoroethanol-free (TFE) and conjugated with glu-
curonide (TFEG)-were found in urine of injected
animals, and if the vinyl moiety was labeled, 14CO2
was found in exhaled air. According to urinary ex-
cretion, TFE and TFEG are the major metabolites
of fluroxene in mice and dog, respectively. The
TFEE/TFAA excretion ratio is approximately 2:1.
TFAA, TFE, and TFEG were also identified in
urine of anesthetized rhesus monkeys (16) and man
(15). However, TFAA was the major metabolite,
and TFE and TFEG were excreted only in traces.
In our laboratory, we administered fluroxene to
nine informed surgical patients (15). The anesthesia
was administered in a closed-circuit absorption sys-
tem by injection ofliquid fluroxene in the circuit by
a Harvard infusion pump, the speed controlled by a
Data-Trak curve follower programmed to maintain
a constant alveolar concentration around 3.3%.
This system allowed us to measure uptake by the
amount offluroxene injected into the circuit, and/or
by measurement of the uptake rate from difference
of fluroxene concentrations in inhaled and exhaled
air and minute ventilation. The anesthesia lasted 77
to 210 min. The administered dose was 32 g (SD =
10), corresponding to an average dose of 0.43 g/kg
(SD = 0.14). Fluroxene concentrations in exhaled
December 1977 225Table 1. HIstory of fluroxene.
Observation
Beginning ofclinical anesthesia
Hepatotoxicity in fasting rats
In vitro metabolism
Toxicity in dog
First report on biotransformation in mice and dog
metabolites: trifluoroethanol glucuronide, free
trifluoroethanol, trifluoroacetic acid, CO2
Biotransformation oflabeled fluroxene in two
volunteers
Postanesthetic death in experimental animals
Postanesthetic toxicity in man (2 cases, one fatal)
Modification offluroxene toxicity by other drugs
Postanesthetic toxicity in man (2 cases, one fatal)
Biotransformation offluroxene in surgical patients
Withdrawn from the market
Exhalation of trifluoroethanol in monkeys
Destruction of cytochrome P-450
Sex differences in anesthetic toxicity
Glutathione depletion
air and minute ventilation were measured for 5
days, and it was calculated that 58% of fluroxene
was exhaled unaltered. Total amount ofTFAA ex-
creted during and following anesthesia was equiva-
lent to 10% of the administered dose of fluroxene,
and the quantity of TFE and TFEG excreted was
equivalent to less than 1% ofthe administered dose.
The fate of 31% offluroxene is unknown.
In another study (16), we anesthetized rhesus
monkeys for 4 hr with fluroxene. During anesthesia
the concentrations of TFAA in urine and in blood
were 27.1 mg-% and 2.57 mg-%, respectively, and
TFE concentrations in urine were 4.11 mg-%, and
in blood less than 3 mg-%. Traces of TFE were
found in exhaled air. If the animals were pretreated
with phenobarbital, the concentrations in urine as
well as in blood increased (TFAA, 49.7 mg-% and
4.22 mg-% respectively; TFEE, 10.9 mg-% and 17
mg-%, respectively). A significant amount of TFE
was exhaled during anesthesia. The TFE concen-
tration in exhaled air increased with exposure dura-
tion. Enhanced fluroxene metabolism was previ-
ously observed in dogs and mice pretreated with
phenobarbital, 3-methylcholanthrene, or 3,4-
benzyprene (5).
When the monkeys were sacrificed at the end of
exposure, a nonvolatile fluorinated compound was
found in all tissues. In pretreated animals the
fluorine concentrations were significantly greater
than in nonpretreated animals. The same observa-
tion was made in similar experiments in mice (19,
20). After exposure, the amount of fluorinated
compound in all tissues of pretreated mice (except
in the liver) kept increasing up to 10 hr, the maximal
survival time (Fig. 1).
No fluoride ion was released by fluroxene
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FIGURE 1. Concentrations of nonvolatile fluorine in mouse tis-
sues following2 hr exposure to 0.8% fluroxene. The bar indi-
cates the fluorine concentration in a pool of organs of two
animals. The numbers under the bars indicate the time inter-
vals (in hours) between end of exposure and sacrifice ofani-
mals. The dagger (t) indicates that all animals were dead.
metabolism since none was found in tissues or ex-
creta of any studied species. There is also indirect
evidence that the trifluoroethyl moiety is not de-
fluorinated: metabolites offluroxene were adminis-
tered to mice, and no changes in citric acid concen-
trations in tissues were observed, which means that
no monofluoro derivatives were formed, since
otherwise the Krebs cycle would be blocked (21).
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226Toxicity of Fluroxene
Fluroxene has been found to be highly toxic to
mice (7, 12, 18-20, 22), dogs, cats, and rabbits (8,
23), but not to man (1, 8, 15). Terminal events in
dogs, cats and rabbits include diarrhea, convulsion,
and reduction in clotting factors. Autopsy revealed
hemorrhagic gastrointestinal mucose, lung conges-
tion, and haemorrhages. Histologic examination of
tissues has shown inflammatory and vascular in-
volvement. Mice anesthetized with fluroxene may
recover from light anesthesia, mortality being re-
lated to concentration used, duration of anesthesia
(7), and sex (18). In mice fluroxene is more toxic in
males than in females. In our experiments, mice
anesthetized for 2 hr with 3% fluroxene recovered
rapidly from anesthesia, within 2 hr became uncon-
scious again, and died within 5 hr in convulsions. In
gross examination, no apparent changes in organs
were observed. Histological examination showed
hepatocellular changes, predominantly centrolobu-
lar vacuolization, moderate fatty metamorphosis,
passive hyperemia, and sinusoidal congestion (19).
Similar hepatotoxicity was observed in rats, but the
fluroxene anesthesia was not fatal (11). There were
no toxic side effects offluroxene in man (1, 8, 15) or
rhesus monkey (16), with the exception of the four
surgical patients mentioned before. Postoperatively
these latter patients suffered from nausea, vomit-
ing, fever,jaundice, and hemorrhagic disorder, and
histologic examination showed centrolobular ne-
crosis and fatty degeneration ofthe liver. In all four
cases, previous extensive drug exposure (such as
phenobarbital, diphenylhydantoin) was involved (9,
10, 13, 14).
Modification of Fluroxene Toxicity
by Other Drugs
Fluroxene anesthesia was fatal in all experimen-
tal animals pretreated with phenobarbital (7, 11,
16). The most remarkable observation is that mon-
keys (16) and rats (11) tolerated fluroxene anes-
thesia without any toxic side effect, but none of the
animals pretreated with phenobarbital survived a
four hour anesthesia. The target organ in rats is the
liver (histological examination revealed massive
liver necrosis), and in monkeys the lung (pink-
staining edema fluid). Hepatotoxicity in pretreated
monkey was indicated only by increasing SGOT
and SGPT in blood.
In contrast, post anesthetic death was reduced in
mice by pretreatment with microsomal enzyme in-
hibitors, such as carbon tetrachloride (12) or
2-allyl-2-isopropylacetamide (24).
Administration of sex hormones reverses the
fluroxene toxicity in male and female mice (18): Es-
tradiol administration reduces toxicity in males,
while testosterone enhances toxicity in females.
Studies in mice (12) and dogs (23) demonstrated
that postanesthetic mortality may be reduced or
abolished by ethanol, and by drugs which affect
ethanol metabolism such as pyrazole, aminotriazol
and disulfiram.
Death resulting from fluroxene anesthesia may
be delayed for 6 hr if the mice are simultaneously
treated with L-cysteine (19).
Toxicity of Fluroxene Metabolites
The toxicity of fluroxene metabolites is much
greater than toxicity offluroxene itself, and is com-
parable to toxicity of chlorinated derivatives which
are metabolites oftrichloroethylene (Table 2). TFE
toxicity is reduced if administered IV (25). The
lethal effect is usually delayed 18-32 hr after
administration. We administered fluroxene in-
traperitoneally in olive oil to white Wistar mice.
The LD.50 was 6.9 g/kg. This means that TFE is 16
times more toxic than fluroxene and 6 times more
toxic than TFAA. Because of its high toxicity,
TFE was studied intensively, mainly in mice (21,
22, 25, 26) and dogs (23). It was concluded that
TFE produces death in a manner indistinguishable
from death resulting from fluroxene anesthesia, and
that like fluroxene, TFE toxicity is depressed by
ethanol administration (23, 25) and accompanied by
an increase of TFEG and decrease of TFAA in
urine (25).
Table 2. LD50 of metabolites administered IP in mice.
LD50, g/kg
Fluroxene Trichloroethylene
X=F X=CI
CX3CH2OH 0.42 0.2
CX3CH (OH)2 0.65
CX3COOH 2.6 2.4
CH2XCOOH 0.0005 0.1
It was demonstrated in mice that, contrary to
fluroxene, TFE toxicity is reduced or not affected
at all by phenobarbital pretreatment, but like
fluroxene, the sex differences in toxicity favor
females (18). Also, toxicity is diminished by ad-
ministration of ethanol and drugs interferring with
ethanol metabolism (25) (carbon tetrachloride,
pyrazol, hydrazide, disulfiram), by administration
of L-cysteine (27), and by halothane pretreatment
(27).
Modification oftrifluoroacetaldehyde toxicity by
drugs was qualitatively similar to TFE, but usually
more profound (21). The effects ofdrugs on toxicity
December 1977 227of fluroxene and its metabolites are summarized in
Table 3.
Table 3. Modification of toxicity of fluroxene
and its metabolites by other drugs.
Toxicity
Drug Species Fluroxene TFE TFAald
Phenobarbital Mice T 0 0
Cats, monkeys,
dogs T
CC14 Mice 4 4 4
2-Allyl-2-iso- Rats 4
propyl-
acetamide
Ethanol Mice, dogs
Pyrozole Mice 4 4 4
Aminotriazol Mice 4 4
Disulfiram Mice 4 4 4
Allopurinol Mice T t
L-Cysteine Mice 4 4
Hydrazide Mice 4 4
Estradiol Mice (male) 4 4
Testosterone Mice (female) T t
Halothane Mice I
Effect of Fluroxene and its
Metabolites on Cellular
Constituents
Massive platelet and fibrinogen depletion was
observed in dogs (8) and in phenobarbital-
pretreated monkeys (16) during and following
fluroxene anesthesia. This has not been observed in
man or in nonpretreated monkeys.
During and following fluroxene exposure,
glutathione was profoundly depleted in blood and
tissues of mice and rats (the depletion in mice was
more extensive) and slightly depleted in blood of
anesthetized monkeys (19). No depletion in human
blood was observed (Our unpublished observation;
tissues of monkeys and man were not examined).
Phenobarbital pretreatment enhanced glutathione
depletion in rodents anesthetized with fluroxene
(19). Glutathione depletion was also observed in
liver and erythrocytes of mice exposed to TFE and
trifluoroacetaldehyde, but no depletion was ob-
served in experiments in vitro (27).
In liver of mice anesthetized with fluroxene,
ATP was depleted, depletion being inversely re-
lated to the amount of TFE in urine (22). TFE or
TFAA administered to guinea pigs also lowered
ATP in liver but did not affect ATP in mouse livers
(26). Fluroxene metabolites also decrease NADPH
concentration in mouse livers and increase concen-
tration of NADP, without changing total concen-
tration of nucleotides (27). TFE and trifluoroacet-
aldehyde also inhibit D-glucose-6-phosphate de-
hydrogenase and significantly decrease the lac-
tate-pyruvate pool in mouse livers. This data leads
to the conclusion that fluroxene metabolites cause
inhibition of anaerobic glycolysis (27).
Mechanisms of Toxicity and
Metabolic Pathways of Fluroxene
The metabolic pathway of fluroxene appears to
be very simple. After splitting of the ether linkage
by microsomal enzymes, the vinyl moiety is ox-
idized to carbon dioxide and the trifluoroethyl moi-
ety is oxidized to TFE. TFE either undergoes de-
toxification by glucuronization or is oxidized to
TFAA by enzymes involved in ethanol metab-
olism, the unstable trifluoroacetaldehyde
being postulated intermediate. Only a few observa-
tions remain to be added in order to complete the
picture of metabolic pathways as they are illus-
trated in Figure 2.
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FIGURE 2. Metabolic pathways offluroxene. The metabolites in
shaded areas are hypothetical. The lines represent the indi-
vidual steps in metabolism, to the left are the enzymes in-
volved, to the right are modifiers of enzyme activity. Trian-
gles in front of modifiers mean stimulation (A) or inhibition
(V) ofenzymatic activity, triangles behind the modifiers indi-
cate increase (A) ordecrease (V) offluroxene toxicity inmice.
P450 is microsomal cytochrome P450 system, MEOS is
microsomal ethanol oxidizing system, ADH is alcohol de-
hydrogenase.
Environmental Health PerspectivesFluroxene metabolites were administered to ro-
dents and male volunteers. It was observed that
TFAA is not further metabolized, and is quanti-
tatively excreted in urine (D. A. Holaday, and
R. Cunnah, personal communication, experiments
in humans). Furthermore, trifluoroacetaldehyde is
oxidized to TFAA and reduced to TFE (21) (ex-
periments in rats), and TFE is oxidized to TFAA
(25) (experiments in mice).
The fate of the vinyl moiety of fluroxene was
recently studied in rats (17, 24, 28). It was shown in
microsomal enzyme preparations that fluroxene
and its saturated homolog, 2,2,2-trifluoroethyl ethyl
ether, bind to cytochrome P-450 but not to cyto-
chrome P-448. In contrast to 2,2,2-trifluoroethyl
ethyl ether, fluroxene destroys cytochrome P-450
by degradation of its heme moiety. Since the de-
struction was prevented by preincubation ofmicro-
somes with carbon monoxide, it was postulated that
cytochrome P-450 is destroyed during the
metabolism of the vinyl moiety. We speculate that
this destruction could be caused by reactive epox-
ide formed from the vinyl group, either after split-
ting of the ether linkage or by epoxidation of the
fluroxene molecule. If trifluoroethoxy epoxide is
formed and bound to cellular constituents, this
could also explain the large fraction of fluorine un-
recovered in patients anesthetized with fluroxene.
(Another explanation could be that trifluorometabo-
lites are bound to poly-L-lysine or proteins, as sug-
gested for halothane) (29, 30).
The toxic effect of fluroxene and 2,2,2-trifluoro-
ethyl ethyl ether was attributed to the trifluoroethyl
moiety, because the toxicity of both ethers is com-
parable (24). Since toxicity of fluroxene is reduced
by all inhibitors of enzymes catalyzing alcohol oxi-
dation or by drugs binding trifluoroacetaldehyde,
and since TFAA is not toxic, the toxicity-limiting
factor in fluroxene metabolism is trifluoro-
acetaldehyde, or its oxidation to TFAA. Trifluoro-
acetaldehyde is also presumably formed from halo-
thane, which is not fatal to experimental animals. It
is believed that trifluoroacetaldehyde was not
proved as a halothane metabolite, for the reason
that it is instantly oxidized to TFAA. However, it
is unlikely that the trifluoroacetaldehyde generated
from halothane and fluroxene would be detoxified
differently.
The genetic and environmental effects ofenzyme
synthesis and activity are today recognized and dif-
ferences in toxicity and metabolism of a variety of
drugs in different species have been reported (31,
32). In most cases, Old World monkeys showed the
closest resemblance to humans (32). Fluroxene is
no exception in this respect. [Surprising was the
dramatic effect of phenobarbital pretreatment on
toxicity and metabolism of tluroxene in rhesus
monkey (16). However, similar information on
other drugs is not available]. Species differences
and the variety of drugs modifying fluroxene toxic-
ity and metabolism are unusually large. This may be
related to the involvement in fluroxene metabolism
of numerous enzymes (Fig. 2) which are enhanced
or inhibited differently by genetic and environmen-
tal factors. For example, it might be expected that
in man, who is exposed to alcoholic beverages, the
alcohol-metabolizing enzymes will react differently
than in experimental animals. Also, induction of
microsomal enzymes which catalyze the initial step
of fluroxene metabolism is not necessarily accom-
panied by increase ofactivity ofthe other enzymes.
This could upset the balance in normal metabolic
pathways offluroxene and might increase the toxic-
ity.
Finally, with respect to mechanisms offluroxene
toxicity following anesthesia, the large dose ad-
ministered has to be kept in mind. For example,
following clinical anesthesia, approximately 15 g
fluroxene undergoes metabolism. This requires a
large amount of oxygen and energy, the transfer of
which employs numerous enzymes and coenzymes,
participating in normal metabolism. Thus sharing of
these resources might result in slowing important
vital processes in the body. The inhibition of
anaerobic glycolysis (27) and increase of fluroxene
toxicity under hypoxic conditions (2) already have
been suggested.
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